Nicorandil improves glomerular injury in rats with mesangioproliferative glomerulonephritis via inhibition of proproliferative and profibrotic growth factors

Journal of Pharmacological Sciences

Volumn 111, Issue 1, 2009, Pages 53-59

  Sudo, Hirokazu ^a   Hirata, Michinori ^a   Kanada, Hirotaka ^a   Yorozu, Keigo ^a   Tashiro, Yoshihito ^a   Serizawa, Ken Ichi ^a   Yogo, Kenji ^a   Kataoka, Motoyuki ^a   Moriguchi, Yoshiyuki ^a   Ishizuka, Nobuhiko ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Anti Thy1 glomerulonephritis; Extracellular matrix; Nicorandil; Proteinuria; Renoprotection

Indexed keywords

COLLAGEN TYPE 1; FIBRONECTIN; GROWTH FACTOR; MESSENGER RNA; NICORANDIL; PLATELET DERIVED GROWTH FACTOR; PROFIBROTIC GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; HISTOPATHOLOGY; KIDNEY HYPERTROPHY; KIDNEY INJURY; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MESANGIUM CELL; NEPHRITIS; NONHUMAN; PROTEIN EXPRESSION; PROTEINURIA; RAT; RENAL PROTECTION;

ANIMALS; BLOOD PRESSURE; CARDIOTONIC AGENTS; CELL PROLIFERATION; COLLAGEN TYPE I; DISEASE MODELS, ANIMAL; FIBRONECTINS; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; ISOANTIBODIES; KIDNEY GLOMERULUS; MALE; NICORANDIL; ORGAN SIZE; PLATELET-DERIVED GROWTH FACTOR; PROTEINURIA; RATS; RATS, INBRED F344; TRANSFORMING GROWTH FACTOR BETA;

EID: 70349504193     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09072FP     Document Type: Article

References (28)

1. Liu PP. Cardiorenal syndrome in heart failure: a cardiologist's perspective. Can J Cardiol. 2008;24 Suppl B:25B-29B.
2. Jefferson JA, Shankland SJ, Pichler RH. Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int. 2008;74: 22-36. (Pubitemid 351841893)
3. Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med. 1988;318:1657-1666.
4. Striker LJ, Doi T, Elliot S, Striker GE. The contribution of glomerular mesangial cells to progressive glomerulosclerosis. Semin Nephrol. 1989;9:318-328. (Pubitemid 20014548)
5. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. Am J Cardiol. 1989;63:18J-24J. (Pubitemid 19161045)
6. Okamura A, Rakugi H, Ohishi M, Yanagitani Y, Shimizu M, Nishii T, et al. Additive effects of nicorandil on coronary blood flow during continuous administration of nitroglycerin. J Am Coll Cardiol. 2005;37:719-725.
7. IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA) randomised trial. Lancet. 2002;359: 1269-1275.
8. Ishii H, Toriyama T, Aoyama T, Takahashi H, Yamada S, Kasuga H, et al. Efficacy of oral nicorandil in patients with endstage renal disease: a retrospective chart review after coronary angioplasty in Japanese patients receiving hemodialysis. Clin Ther. 2007;29:110-122. (Pubitemid 46414024)
9. Segawa K, Minami K, Shiga Y, Shiraishi M, Sata T, Nakashima Y, et al. Inhibitory effects of nicorandil on rat mesangial cell proliferation via the protein kinase G pathway. Nephron. 2001; 87:263-268. (Pubitemid 32268568)
10. Bagchus WM, Jeunink MF, Elema JD. The mesangium in anti- Thy-1 nephritis. Influx of macrophages, mesangial cell hypercellularity, and macromolecular accumulation. Am J Pathol. 1990;137:215-223.
11. Makibayashi K, Tatematsu M, Hirata M, Fukushima N, Kusano K, Ohashi S, et al. A Vitamin D Analog Ameliorates Glomerular Injury on Rat Glomerulonephritis. Am J Pathol. 2001;158:1733-1741. (Pubitemid 32422938)
12. Floege J, Johnson RJ, Gordon K, Iida H, Pritzl P, Yoshimura A, et al. Increased synthesis of extracellular matrix in mesangial proliferative nephritis. Kidney Int. 1991;40:477-488.
13. Coppo R, D'Amico G. Factors predicting progression of IgA nephropathies. J Nephrol. 2005;18:503-512. (Pubitemid 41824469)
14. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. N Engl J Med. 1994;331:1286-1292. (Pubitemid 24333194)
15. Johnson RJ, Floege J, Couser WG, Alpers CE. Role of plateletderived growth factor in glomerular disease. J Am Soc Nephrol. 1993;4:119-128.
16. Peters H, Daig U, Martini S, Rückert M, Schäper F, Liefeldt L, et al. NO mediates antifibrotic actions of L-arginine supplementation following induction of anti-thy1 glomerulonephritis. Kidney Int. 2003;64:509-518. (Pubitemid 36871922)
17. Wang-Rosenke Y, Neumayer HH, Peters H. NO signaling through cGMP in renal tissue fibrosis and beyond: key pathway and novel therapeutic target. Curr Med Chem. 2008;15:1396-1406. (Pubitemid 351997790)
18. Wang Y, Krämer S, Loof T, Martini S, Kron S, Kawachi H, et al. Stimulation of soluble guanylate cyclase slows progression in anti-thy1-induced chronic glomerulosclerosis. Kidney Int. 2005; 68:47-61. (Pubitemid 43181363)
19. Ishizuka N, Saito K, Akima M, Matsubara S, Saito M. Hypotensive interaction of sildenafil and nicorandil in rats through the cGMP pathway but not by K(ATP) channel activation. Jpn J Pharmacol. 2000;84:316-324. (Pubitemid 32000458)
20. Minamiyama Y, Takemura S, Hai S, Suehiro S, Okada S, Funae Y. Nicorandil elevates tissue cGMP levels in a nitric-oxideindependent manner. J Pharmacol Sci. 2007;103:33-39. (Pubitemid 46175593)
21. + channel. Kidney Int. 2002;61:1739-1749.
22. + channel subunit Kir6.1 in rat kidney. Eur J Histochem. 2007;51:43-51.
23. Xu J, Nagata K, Obata K, Ichihara S, Izawa H, Noda A, et al. Nicorandil promotes myocardial capillary and arteriolar growth in the failing heart of Dahl salt-sensitive hypertensive rats. Hypertension. 2005;46:719-724. (Pubitemid 43186744)
24. Horinaka S, Kobayashi N, Yagi H, Mori Y, Matsuoka H. Nicorandil but not ISDN upregulates endothelial nitric oxide synthase expression, preventing left ventricular remodeling and degradation of cardiac function in Dahl salt-sensitive hypertensive rats with congestive heart failure. J Cardiovasc Pharmacol. 2006;47:629-635. (Pubitemid 44309654)
25. Sakai K, Akima M, Katsuyama I. Effects of nicorandil on experimentally induced gastric ulcers in rats: a possible role of KATP channels. Jpn J Pharmacol. 1999;79:51-57. (Pubitemid 29060547)
26. Ingelsson E, Sundström J, Lind L, Risérus U, Larsson A, Basu S, et al. Low-grade albuminuria and the incidence of heart failure in a community-based cohort of elderly men. Eur Heart J. 2007;28:1739-1745. (Pubitemid 47227087)
27. Arnlöv J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation. 2005;112:969-975. (Pubitemid 41170264)
28. Lee TM, Chang NC. Effect of nicorandil on proteinuria in well controlled hypertensive patients. J Hypertens. 2009;27:618-625.